HERDOO2 decision rule for recurrent venous thromboembolism
Clinical decision rule to identify patients at low risk of recurrent venous thromboembolism after 5-7 months of oral anticoagulant therapy.
HERDOO2 stands for: hyperpigmentation, edema, redness, D-dimer, obesity, older age, 2 scores.
Research authors: Marc A Rodger, Susan R Kahn, Philip S Wells, David A Anderson, Isabelle Chagnon, Grégoire Le Gal, Susan Solymoss, Mark Crowther, Arnaud Perrier, Richard White, Linda Vickars, Tim Ramsay, Marisol T. Betancourt, Michael J. Kovacs
Version: 1.4
  • Public
  • Cardiology
  • {{ modelType }}
  • Details
  • Validate model
  • Save input
  • Load input

Calculate the result

Set more parameters to perform the calculation

HERDOO2 risk score: points

{{ resultSubheader }}
{{ chart.title }}
Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

Conditional information

Interpretation of results:

  • In a study by Rodger et al (2008) including 646 patients with a first unprovoked venous thromboembolism (VTE) event, an annual risk of VTE recurrence of 9.3% [95% confidence interval (CI) 7.7–11.3%) was recorded in the whole cohort, and of 13.7% in men.
  • On the basis of these results, the authors recommend a long-term anticoagulant treatment as always indicated for all men.
  • Women with a total risk score of 0 to 1 had an annual risk of recurrence of 1.6% (95% CI 0.3-4.6%), whereas those who had a score of 2 or more had an annual risk of 14.1% (95% CI 10.9–17.3%) and deserved, according to the authors, an indefinite anticoagulation.


{{ file.classification }}
PRO
Note
Notes are only visible in the result download and will not be saved by Evidencio

This model is provided for educational, training and information purposes. It must not be used to support medical decision making, or to provide medical or diagnostic services. Read our full disclaimer.

Underlying models Part of
Comments
Comment
Please enter a comment
Comments are visible to anyone

Model feedback

No feedback yet 1 Comment {{ model.comments.length }} Comments
On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
{{ comment.content }}
logo

Please sign in to enable Evidencio print features

In order to use the Evidencio print features, you need to be logged in.
If you don't have an Evidencio Community Account you can create your free personal account at:

https://www.evidencio.com/registration

Printed results - Examples {{ new Date().toLocaleString() }}

Evidencio Community Account Benefits

With an Evidencio Community account you can:

  • Create and publish your own prediction models.
  • Share your prediction models with your colleagues, research group, organization or the world.
  • Review and provide feedback on models that have been shared with you.
  • Validate your models and validate models from other users.
  • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction models and their data.
  • Use patient specific protocols and guidelines based on sequential models and decision trees.
  • Stay up-to-date with new models in your field as they are published.
  • Create your own lists of favorite models and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.

Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.
Terms & Conditions | Privacy Policy | Disclaimer | Contact | Refuse cookies |
Evidencio v3.25 © 2015 - 2024 Evidencio. All Rights Reserved